| ID | Peptide Seq | Site Residue | Position in Peptide | Position in Protein |
|---|---|---|---|---|
| 10002707 | 105 | |||
| 10026678 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | T | 16 | 105 |
| 10027736 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | S | 12 | 101 |
| 10027876 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | T | 15 | 104 |
| 10034114 | SSSSAEHPGASKPPISSSSMTSR | S | 16 | 49 |
| 10037354 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | 101 | ||
| 10037545 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | 101 | ||
| 10037546 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | 105 |
| ID | Method | Analytical Throughput | Ambiguity | Species | Sample Type | Condition | log2Ratio | P Value | Data Source PMID | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| 10002707 | MS | HTP | unambiguous | human | HeLa cells | Mitotic exit/Early mitosis | 100 | 34161081 | The p value was -log10p in original paper. | |
| 10026678 | MS | HTP | unambiguous | human | HeLa cells | 35254053 | ||||
| 10027736 | MS | HTP | unambiguous | human | HeLa cells | 35254053 | ||||
| 10027876 | MS | HTP | unambiguous | human | HeLa cells | 35254053 | ||||
| 10034114 | MS, site-directed mutagenesis | LTP | unambiguous | human | HEK 293T cells | 37886470 | ||||
| 10037354 | MS | HTP | unambiguous | human | HEK 293T cells | TMG/control | -0.736965594 | 30620550 | Peptide quantification value was applied to each modification site | |
| 10037545 | MS | HTP | unambiguous | human | HepG2 cells | orafenib sensitive/resistant | -3.321928095 | 30620550 | Peptide quantification value was applied to each modification site | |
| 10037546 | MS | HTP | unambiguous | human | HepG2 cells | orafenib sensitive/resistant | -3.321928095 | 30620550 | Peptide quantification value was applied to each modification site |
| ID | Peptide Seq | Site Residue | Position in Peptide | Position in Protein | Method | Analytical Throughput | Ambiguity | Species | Sample Type | Data Source PMID | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10002707 | 105 | MS | HTP | unambiguous | human | HeLa cells | 34161081 | The p value was -log10p in original paper. | |||
| 10026678 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | T | 16 | 105 | MS | HTP | unambiguous | human | HeLa cells | 35254053 | |
| 10027736 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | S | 12 | 101 | MS | HTP | unambiguous | human | HeLa cells | 35254053 | |
| 10027876 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | T | 15 | 104 | MS | HTP | unambiguous | human | HeLa cells | 35254053 | |
| 10034114 | SSSSAEHPGASKPPISSSSMTSR | S | 16 | 49 | MS, site-directed mutagenesis | LTP | unambiguous | human | HEK 293T cells | 37886470 | |
| 10037354 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | 101 | MS | HTP | unambiguous | human | HEK 293T cells | 30620550 | Peptide quantification value was applied to each modification site | ||
| 10037545 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | 101 | MS | HTP | unambiguous | human | HepG2 cells | 30620550 | Peptide quantification value was applied to each modification site | ||
| 10037546 | VPVSQTPAINVSVPTTLPSATQVPMEVLK | 105 | MS | HTP | unambiguous | human | HepG2 cells | 30620550 | Peptide quantification value was applied to each modification site |